All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.


 Glucagonoma is an uncommon neuroendocrine tumor that begins only in the pancreas and presumably represents 1% of every neuroendocrine tumor. Threatening glucagonomas are islet cell pancreatic tumors that are found on account of glucagonoma disorder (in which the glucagonoma self-rulingly secretes glucagon), in light of nearby mass impacts, or by chance. Glucagonomas start from the alpha-2 cells of the pancreas. Unregulated creation (overproduction) of peptide hormones and development factors, which are not typically communicated in the tissue of root, is normal for neuroendocrine tumors. Strange creation of these bioactive peptides can prompt critical fundamental harmful outcomes and to the advancement of further tumor development. Despite the fact that the reason for glucagonoma is obscure, Glucagonoma results from the overproduction of glucagon, a peptide hormone situated in the pancreatic alpha cells. Great side effects incorporate, yet are not restricted to, necrolytic transient erythema (NME), diabetes mellitus, and weight reduction

High Impact List of Articles

Relevant Topics in General Science

Awards Nomination

Select your language of interest to view the total content in your interested language

Table of Contents

Google Scholar citation report
Citations : 875

BioTechnology: An Indian Journal received 875 citations as per Google Scholar report

Indexed In

  • CASS
  • Google Scholar
  • Open J Gate
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Cosmos IF
  • Directory of Research Journal Indexing (DRJI)
  • Secret Search Engine Labs
  • Euro Pub

View More

Recommended Conferences

27th European Biotechnology Congress

Rome, Italy